Skip to content

Board of Directors

lidds-Jan-Tornell-people

Jan Törnell

Chairman of the Board since 2015

Born: 1960

Education: MD and PhD in Physiology, University of Gothenburg

Other assignments: CEO and board member of AB Innoext. Chairman of Glactone Pharma AB and Glactone Pharma Development AB, board member of Abliva AB and Diaprost AB

Work experience: Former Vice President of Global Strategy for AstraZeneca Oncology & Infection. Professor of Physiology at the Sahlgrenska Academy, University of Gothenburg. Partner in P.U.L.S. and member of the investment committee. Associate professor in Physiology, Gothenburg University.

Holdings: 52 909 shares, 0 warrants

Independent in relation to LIDDS AB (publ), its management and the principal shareholders

lidds-David-Bejker-people

David Bejker

Board member since 2019, Chairman of the Audit committee

Born: 1975

Education: MSc from the Stockholm School of Economics

Other assignments: CEO of Affibody Medical AB and board member of Abliva AB and Amylonix AB

Work experience: CEO of Affibody Medical AB, a company that develops innovative protein drugs, since 2008. Previously at HealthCap, a specialized life science investor.

Holdings: 5 624 shares, 0 warrants

Independent in relation to LIDDS AB (publ), its management and the principal shareholders

lidds-Maria-Forss-people

Maria Forss

Board member since 2015, member of the Audit Committee since 2021

Born: 1972

Education: Master’s degree in Economics from the School of Business, Economics and Law at Gothenburg University and Concordia University, Montreal. Executive education at Stanford University, USA. Certified board member via Styrelseinstitutet and advanced board training via StyrelseAkademin

Other assignments: Senior Vice President Consumables Division, Vitrolife

Work experience: Vice President Business Development and Global Marketing at Vitrolife. Board member of Oncorena AB. Head of Business Development of Aquilion (former P.U.L.S.), CEO Duocort Pharma and management roles within Astra Zeneca.

Holdings: 26 186 shares, 0 warrants

Independent in relation to LIDDS AB (publ), its management and the principal shareholders

lidds-Daniel-Lifveredson-people

Daniel Lifveredson

Board member since 2017

Born: 1976

Education: Master of Science in Industrial Engineering and Management, Chalmers University of Technology in Gothenburg

Other assignments: CEO and owner of Excore AB

Work experience: Worked with Excore as a base since 1998. Excore is active in advising corporate transactions in the segment of medium-sized companies. Long experience in international business. In addition to Excore, Daniel Lifveredson is involved as a partner in a number of businesses.

Holdings: 2 640 929 shares, 0 warrants

Independent in relation to LIDDS AB (publ), its management and the principal shareholders

Johan Lund

Board member since 2022

Born: 1957

Education: MD/PhD Karolinska Institute, Stockholm.

Other assignments: Co-Founder of KyNexis Medicine Development AB and founder of MBS Pharma, CSO and Chairman of the Board of Aqilion, Chairman of the Board of NEOGAP Therapeutics AB, board member and chairman of the remuneration committee of Olink Holding (Nasdaq NYC), board member of Genagon Therapeutics AB and Pelago Bioscience AB.

Work Experience: Former VP of Immunology & Inflammation Research & Early Development, Celgene; SVP and CSO of Immunology & Inflammation, Pfizer; VP of CNS & Pain Research, AstraZeneca and VP Respiratory & Inflammation Research, AstraZeneca. Professor & Chairman, Department of Anatomy & Cell Biology, Medical Faculty, University of Bergen; Associate Professor, Department of Medical Nutrition, Karolinska Institute.

Holdings: 0 Shares

Independent in relation to LIDDS AB (publ), its management and the principal shareholders

Max Mitteregger

Board member since 2022

Born: 1963

Education: Economist

Other assignments: CEO Galba Holding AB

Work Experience: Worked as an Institutional Broker at Carnegie and co-founder of ABGSC. Since 2005 founder of MMKAP AS and manager of the hedge fund Gladiator

Holdings: 750,000 shares

Independent in relation to LIDDS AB (publ), its management and the principal shareholders